Aktuellt
SENASTE
Redeye comments on Active Biotech's Q3 report. During the quarter, Active Biotech reported laquinimod concentrations in the vitreous segment of the eye and a rights issue. The rights issue can fund the company through the completion of the laquinimod's biodistribution study in 2025, which may position it for a licensing deal.
LÄS MER
